After the consent form has been signed and the baseline data collected, the participants will be assigned to either active or inactive arms by the NH&MRC Clinical Trials Centre (CTC) located at Sydney University. Devices will come from a pool of seventy devices, which have been supplied by BiometÒ Australia and are commercially known as the EBI Bone Healing System®. Thirty-five of these devices will be active and thirty-five inactive, and they will be randomly numbered from 1 to 70 by the CTC. The CTC will have the code for active and inactive devices and will conduct the randomisation process using the statistical technique of minimisation, a dynamic allocation process designed to balance known risk factors across treatment arms. The two factors that will be minimised for are the recruiting hospital and whether the injury was closed or open. A device will then be randomly assigned from the available pool of either active or inactive devices, and this assigned device will then be fitted to the patient. The researchers, company representatives, surgeons and patients will all remain blinded to active/inactive arms until all the data have been collected and analysed.